LIFEVANTAGE CORP Excess Tax Benefit from Share-based Compensation, Financing Activities
LIFEVANTAGE CORP (LFVN) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $0 for the 12-month period ending 2018-06-30, per its 10-K filed 2018-08-15.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2018-08-15
- LIFEVANTAGE CORP excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-06-30 was $1.38M.
- LIFEVANTAGE CORP excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-03-31 was -$1.38M.
- LIFEVANTAGE CORP excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
- LIFEVANTAGE CORP excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-09-30 was $0.00.
- LIFEVANTAGE CORP excess tax benefit from share-based compensation, financing activities for fiscal 2018 was $0.00.
- LIFEVANTAGE CORP excess tax benefit from share-based compensation, financing activities for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- LIFEVANTAGE CORP excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $266.00K, a 107.81% increase from fiscal 2015.
- LIFEVANTAGE CORP excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $128.00K, a 80.46% decline from fiscal 2014.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2018-06-30 | $0.00 10-K · filed 2018-08-15 | ||||
| 2017-06-30 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-15 | $0.00 derived: sum of 2 quarters · filed 2018-08-15 | $0.00 derived: sum of 3 quarters · filed 2018-08-15 | $0.00 10-K · filed 2018-08-15 | |
| 2017-03-31 | -$1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10 | -$1.38M derived: sum of 2 quarters · filed 2017-05-10 | -$1.38M 10-Q · filed 2017-05-10 | -$1.48M derived: sum of 4 quarters · filed 2018-08-15 | |
| 2016-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-08 | $0.00 10-Q · filed 2017-02-08 | -$95.00K derived: sum of 3 quarters · filed 2018-08-15 | -$139.00K derived: sum of 4 quarters · filed 2018-08-15 | |
| 2016-09-30 | $0.00 10-Q · filed 2016-12-12 | -$95.00K derived: sum of 2 quarters · filed 2018-08-15 | -$139.00K derived: sum of 3 quarters · filed 2018-08-15 | $285.00K derived: sum of 4 quarters · filed 2018-08-15 | |
| 2016-06-30 | -$95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-15 | -$139.00K derived: sum of 2 quarters · filed 2018-08-15 | $285.00K derived: sum of 3 quarters · filed 2018-08-15 | $266.00K 10-K · filed 2018-08-15 | |
| 2016-03-31 | -$44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10 | $380.00K derived: sum of 2 quarters · filed 2017-05-10 | $361.00K 10-Q · filed 2017-05-10 | $341.00K derived: sum of 4 quarters · filed 2017-09-07 | |
| 2015-12-31 | $424.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-08 | $405.00K 10-Q · filed 2017-02-08 | $385.00K derived: sum of 3 quarters · filed 2017-09-07 | $533.00K derived: sum of 4 quarters · filed 2017-09-07 | |
| 2015-09-30 | -$19.00K 10-Q · filed 2016-12-12 | -$39.00K derived: sum of 2 quarters · filed 2017-09-07 | $109.00K derived: sum of 3 quarters · filed 2017-09-07 | $109.00K derived: sum of 4 quarters · filed 2017-09-07 | |
| 2015-06-30 | -$20.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-09-07 | $128.00K derived: sum of 2 quarters · filed 2017-09-07 | $128.00K derived: sum of 3 quarters · filed 2017-09-07 | $128.00K 10-K · filed 2017-09-07 | |
| 2015-03-31 | $148.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2016-07-19 | $148.00K derived: sum of 2 quarters · filed 2016-07-19 | $148.00K 10-Q/A · filed 2016-07-19 | $803.00K derived: sum of 4 quarters · filed 2016-12-12 | |
| 2014-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-09 | $0.00 10-Q · filed 2016-02-09 | $655.00K derived: sum of 3 quarters · filed 2016-12-12 | ||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-04 | $655.00K derived: sum of 2 quarters · filed 2016-12-12 | |||
| 2014-06-30 | $655.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-12 | $655.00K 10-K · filed 2016-12-12 | |||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-06 | ||||
| 2013-06-30 | $1.41M 10-K · filed 2015-09-01 | ||||
| 2012-06-30 | $388.00K 10-K · filed 2014-09-10 | $387.61K 10-K · filed 2012-09-10 | |||
| 2011-06-30 | $0.00 10-K · filed 2013-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |